{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/KNSA/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-10T11:44:29.279Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9221,"canonical_name":"Kiniksa Pharmaceuticals International, plc","cik":"0001730430","uei":null,"lei":null,"duns":null,"ticker":"KNSA"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":21,"clinical":1},"count":22,"timeline":[{"ts":"2026-07-06","kind":"sec.filing","form_type":"3","title":"3 — Kiniksa Pharmaceuticals International, plc — 2026-07-06","url_slug":"/sec/cik-0001730430/3/0002143491-26-000002","accession_number":"0002143491-26-000002","importance":30},{"ts":"2026-07-06","kind":"sec.filing","form_type":"4","title":"4 — Kiniksa Pharmaceuticals International, plc — 2026-07-06","url_slug":"/sec/cik-0001730430/4/0002143491-26-000004","accession_number":"0002143491-26-000004","importance":30},{"ts":"2026-06-01","kind":"sec.insider.c","reporter":"Patel Sanj K","title":"CHAIRMAN & CEO","shares":900000,"price_per_share":null,"usd_value":0,"security_title":"Class A Ordinary Share","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"BAKER BROS. ADVISORS LP","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"667, L.P.","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"Baker Bros. Advisors (GP) LLC","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"Baker Brothers Life Sciences LP","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"BAKER FELIX","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"BAKER JULIAN","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"BAKER BROS. ADVISORS LP","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"667, L.P.","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"Baker Bros. Advisors (GP) LLC","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"Baker Brothers Life Sciences LP","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"BAKER FELIX","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.a","reporter":"BAKER JULIAN","title":null,"shares":6078,"price_per_share":0,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.m","reporter":"Cole G Bradley","title":"","shares":2799,"price_per_share":null,"usd_value":0,"security_title":"Class A Ordinary Share","importance":15},{"ts":"2026-05-29","kind":"sec.insider.m","reporter":"Popovits Kimberly J","title":"","shares":2799,"price_per_share":null,"usd_value":0,"security_title":"Class A Ordinary Share","importance":15},{"ts":"2026-05-29","kind":"sec.insider.m","reporter":"Quart Barry D","title":"","shares":2799,"price_per_share":null,"usd_value":0,"security_title":"Class A Ordinary Share","importance":15},{"ts":"2026-05-29","kind":"sec.insider.m","reporter":"Malley Thomas","title":"","shares":2799,"price_per_share":null,"usd_value":0,"security_title":"Class A Ordinary Shares","importance":15},{"ts":"2026-05-29","kind":"sec.insider.m","reporter":"Levy Richard S","title":"","shares":2799,"price_per_share":null,"usd_value":0,"security_title":"Class A Ordinary Share","importance":15},{"ts":"2026-05-29","kind":"sec.insider.m","reporter":"McCain Tracey L","title":"","shares":2799,"price_per_share":null,"usd_value":0,"security_title":"Class A Ordinary Share","importance":15},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Kiniksa Pharmaceuticals International, plc","title":"Phase 2/3 Study of KPL-387 in Recurrent Pericarditis","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT07010159","excerpt":"[\"Pericarditis\",\"Pericarditis Acute\",\"Recurrent Pericarditis\"]","importance":60}]}